Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Net Cash Flow (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of Net Cash Flow data on record, last reported at -$29.0 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 172.5% year-over-year to -$29.0 million; the TTM value through Dec 2025 reached -$96.0 million, down 23.08%, while the annual FY2025 figure was -$96.0 million, 45.45% down from the prior year.
  • Net Cash Flow reached -$29.0 million in Q4 2025 per INDV's latest filing, down from -$23.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $40.0 million in Q4 2024 and bottomed at -$68.0 million in Q1 2024.